Shares in Amgen were down nearly 7% after close of trading yesterday after the company’s heart failure drug omecamtiv mecarbil disappointed in a large phase 3 trial. Take a look at Amgen’s ...

Bayer has added another phase 3 trial into its registration ... signalling growing confidence in a drug that generated mixed results in phase 2. The new OCEANIC-AFINA study will enrol patients ...

In a significant advancement for Parkinson's disease (PD) treatment, NeuroDerm Ltd., a subsidiary of Mitsubishi Tanabe Pharma Corporation, has unveiled the results of the Phase 3 BouNDless trial ...

Citing data from its EMERALD-1 Phase 3 ... trial indicated no new safety findings, and the safety profiles of Imfinzi and bevacizumab were in line with the known tolerability profiles of each drug ...

The CardiAMP HF Trial is assessing the safety and effectiveness of the CardiAMP ® Cell Therapy System for HFrEF, with the potential to reduce all cause death, future hospitalizations, enhance ...

Three phase 3 trials of combinations including datopotamab deruxtecan for the treatment of non–small cell lung cancer are beginning.

The first patients have been dosed in three global, randomized phase 3 trials evaluating the efficacy and safety of datopotamab deruxtecan (Dato-DXd)- ...

A new type of targeted medicine has shown ‘remarkable’ benefits for patients with advanced breast cancer in a major phase III clinical trial. The drug capivasertib combined with hormone therapy ...

This is a clinical setting with a patient population where PD-1 monoclonal antibodies have previously been unsuccessful in Phase III global clinical trials ... important new drugs to patients ...

United States Food and Drug Administration ... approval of 64 Cu-SAR-bisPSMA as a new diagnostic imaging agent in prostate cancer. The aim of the Phase III trial is to investigate the ability ...

The Data Monitoring Committee recommended to continue the clinical trial without modification of the current protocol, based on the pre-planned ...